{
  "success": true,
  "pagesUsed": [
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    23,
    24,
    25,
    26,
    27,
    28,
    29
  ],
  "modelUsed": "gemini-3-flash-preview",
  "studyDesignStructure": {
    "studyArms": [
      {
        "id": "arm_1",
        "name": "Nivolumab Arm",
        "type": {
          "code": "Experimental Arm",
          "codeSystem": "USDM",
          "decode": "Experimental Arm"
        },
        "instanceType": "StudyArm",
        "description": "Nivolumab 240 mg administered as a 30-minute IV infusion every 2 weeks until disease progression or unacceptable toxicity."
      },
      {
        "id": "arm_2",
        "name": "Sorafenib Arm",
        "type": {
          "code": "Active Comparator Arm",
          "codeSystem": "USDM",
          "decode": "Active Comparator Arm"
        },
        "instanceType": "StudyArm",
        "description": "Sorafenib 400 mg administered orally twice a day (BID) until disease progression or unacceptable toxicity."
      }
    ],
    "studyCells": [
      {
        "id": "cell_1",
        "armId": "arm_1",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_1"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_2",
        "armId": "arm_1",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_2"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_3",
        "armId": "arm_1",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_3"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_4",
        "armId": "arm_2",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_4"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_5",
        "armId": "arm_2",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_5"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_6",
        "armId": "arm_2",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_6"
        ],
        "instanceType": "StudyCell"
      }
    ],
    "studyCohorts": [
      {
        "id": "cohort_1",
        "name": "HCV-HCC",
        "instanceType": "StudyCohort",
        "characteristic": "Active or resolved HCV infection as evidenced by detectable HCV RNA or antibody"
      },
      {
        "id": "cohort_2",
        "name": "HBV-HCC",
        "instanceType": "StudyCohort",
        "characteristic": "Resolved or Chronic HBV infection with HBV DNA < 100 IU/mL and on antiviral therapy"
      },
      {
        "id": "cohort_3",
        "name": "Non-viral HCC",
        "instanceType": "StudyCohort",
        "characteristic": "HCC with no history of hepatitis virus infection"
      }
    ],
    "studyElements": [
      {
        "id": "elem_1",
        "name": "Nivolumab Arm - Screening",
        "instanceType": "StudyElement",
        "description": "Treatment period for Nivolumab Arm during Screening"
      },
      {
        "id": "elem_2",
        "name": "Nivolumab Arm - Treatment Phase",
        "instanceType": "StudyElement",
        "description": "Treatment period for Nivolumab Arm during Treatment Phase"
      },
      {
        "id": "elem_3",
        "name": "Nivolumab Arm - Follow-up Phase",
        "instanceType": "StudyElement",
        "description": "Treatment period for Nivolumab Arm during Follow-up Phase"
      },
      {
        "id": "elem_4",
        "name": "Sorafenib Arm - Screening",
        "instanceType": "StudyElement",
        "description": "Treatment period for Sorafenib Arm during Screening"
      },
      {
        "id": "elem_5",
        "name": "Sorafenib Arm - Treatment Phase",
        "instanceType": "StudyElement",
        "description": "Treatment period for Sorafenib Arm during Treatment Phase"
      },
      {
        "id": "elem_6",
        "name": "Sorafenib Arm - Follow-up Phase",
        "instanceType": "StudyElement",
        "description": "Treatment period for Sorafenib Arm during Follow-up Phase"
      }
    ],
    "summary": {
      "armCount": 2,
      "cellCount": 6,
      "cohortCount": 3,
      "elementCount": 6
    },
    "studyDesign": {
      "id": "sd_1",
      "name": "Study Design",
      "instanceType": "InterventionalStudyDesign",
      "trialIntentTypes": [
        {
          "code": "Treatment",
          "codeSystem": "USDM",
          "decode": "Treatment"
        }
      ],
      "trialType": {
        "code": "Interventional",
        "codeSystem": "USDM",
        "decode": "Interventional"
      },
      "blindingSchema": {
        "code": "Open Label",
        "codeSystem": "USDM",
        "decode": "Open Label"
      },
      "maskedRoles": [
        "Outcome Assessor"
      ],
      "randomizationType": {
        "code": "Randomized",
        "codeSystem": "USDM",
        "decode": "Randomized"
      },
      "allocationRatio": {
        "ratio": "1:1"
      },
      "stratificationFactors": [
        "Etiology (HCV vs. non-HCV)",
        "Vascular invasion and/or extrahepatic spread (present vs. absent)",
        "Geography (Asia vs. Non-Asia)"
      ],
      "controlType": {
        "code": "Active Control",
        "codeSystem": "USDM",
        "decode": "Active Control"
      },
      "armIds": [
        "arm_1",
        "arm_2"
      ],
      "cohortIds": [
        "cohort_1",
        "cohort_2",
        "cohort_3"
      ],
      "therapeuticAreas": [
        "Oncology",
        "Hepatology"
      ]
    }
  },
  "rawResponse": {
    "studyDesign": {
      "type": "Interventional",
      "trialIntentTypes": [
        "Treatment"
      ],
      "blinding": {
        "schema": "Open Label",
        "maskedRoles": [
          "Outcome Assessor"
        ]
      },
      "randomization": {
        "type": "Randomized",
        "allocationRatio": "1:1",
        "stratificationFactors": [
          "Etiology (HCV vs. non-HCV)",
          "Vascular invasion and/or extrahepatic spread (present vs. absent)",
          "Geography (Asia vs. Non-Asia)"
        ]
      },
      "controlType": "Active Control",
      "therapeuticAreas": [
        "Oncology",
        "Hepatology"
      ]
    },
    "arms": [
      {
        "name": "Nivolumab Arm",
        "type": "Experimental Arm",
        "description": "Nivolumab 240 mg administered as a 30-minute IV infusion every 2 weeks until disease progression or unacceptable toxicity.",
        "isTitration": false,
        "doseEpochs": null
      },
      {
        "name": "Sorafenib Arm",
        "type": "Active Comparator",
        "description": "Sorafenib 400 mg administered orally twice a day (BID) until disease progression or unacceptable toxicity.",
        "isTitration": false,
        "doseEpochs": null
      }
    ],
    "cohorts": [
      {
        "name": "HCV-HCC",
        "characteristic": "Active or resolved HCV infection as evidenced by detectable HCV RNA or antibody"
      },
      {
        "name": "HBV-HCC",
        "characteristic": "Resolved or Chronic HBV infection with HBV DNA < 100 IU/mL and on antiviral therapy"
      },
      {
        "name": "Non-viral HCC",
        "characteristic": "HCC with no history of hepatitis virus infection"
      }
    ],
    "epochs": [
      {
        "name": "Screening",
        "description": "Begins with signing of ICF; includes eligibility assessment and tumor tissue submission."
      },
      {
        "name": "Treatment Phase",
        "description": "Begins with randomization; subjects receive either Nivolumab or Sorafenib until progression or toxicity."
      },
      {
        "name": "Follow-up Phase",
        "description": "Includes two safety visits (35 and 80 days post-last dose) and survival follow-up every 3 months."
      }
    ]
  }
}